Stephen E Epstein

US Patent:

6595979, Jul 22, 2003

Filed:

Oct 23, 2001

Appl. No.:

09/999765

Inventors:

Stephen Epstein - Rockville MD
Shmuel Fuchs - Rockville MD
Ran Kornowski - Ramat-Hasharon, IL

Assignee:

Myocardial Therapeutics, Inc. - San Diego CA

International Classification:

A61M 3100

US Classification:

604506, 604522

Abstract:

Methods for aspiration and filtering of a bodily fluid containing undesired components are provided and for treatment of the bodily fluids in a sterile environment in preparation for reinjection of treated aspirate into a donor subject. The invention methods are particularly designed to facilitate transfection of aspirated cells with angiogenesis promoting molecules without danger to the technician or the donor prior to reinjection of the treated cells, either percutaneously or via a surgical opening via a catheter or injection needle. A pressure actuator attached to the sterile container is used to express treated fluids in precisely controlled volumes. The invention methods include delivery of treated fluids using a hand-held device with audible cues that correspond to an operator-selected injection volume and/or audible cues that correspond to needle penetration depth selected by the operator.

US Patent:

6682728, Jan 27, 2004

Filed:

Oct 13, 1993

Appl. No.:

08/136113

Inventors:

Toren Finkel - Bethesda MD
Raul G. Guzman - Rockville MD
Ronald G. Crystal - Potomac MD
Stephen E. Epstein - Rockville MD

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

A01N 6300

US Classification:

424 932, 424 936, 4353201

Abstract:

The present invention provides a method of selectively expressing DNA in neointimal cells in an injured blood vessel of a subject comprising administering a replication-deficient recombinant adenovirus which functionally encodes the DNA to the blood vessel at the site of injury, such that the adenovirus remains at the site of injury for a time sufficient for the adenovirus to selectively infect neointimal cells and thereby selectively express the DNA in neointimal cells. In particular, the invention provides administering a replication-deficient recombinant adenovirus which functionally encodes a DNA encoding a protein or an antisense ribonucleic acid. This method can be used to treat restenosis and, relatedly, prevent neointimal cell proliferation.

US Patent:

6835193, Dec 28, 2004

Filed:

Oct 23, 2001

Appl. No.:

10/000851

Inventors:

Stephen Epstein - Rockville MD
Shmuel Fuchs - Rockville MD
Ran Kornowski - Ramat-Hasharon, IL

Assignee:

Myocardial Therapeutics, Inc. - La Jolla CA

International Classification:

A61M 3100

US Classification:

604507, 604117, 60416401

Abstract:

A flexible tissue injection catheter is used to accomplish injections at a precisely controlled depth of precisely controlled volumes of a therapeutic or diagnostic agent into an interior body cavity, such as the epicardium or myocardium of the heart. In one embodiment, the invention method includes repeated injections at spaced intervals along the myocardium or epicardium of sterile fluid containing autologous bone marrow aspirate to promote angiogenesis. For myocardial injection, depth penetration is controlled by using a catheter that allows the operator to control depth penetration by means of an adjustable needle stop attached to the catheter handle. In another embodiment depth penetration during epicardial injections is controlled by use of an injection catheter having an operator-controlled adjustable needle stop that produces a sensible signal, such as a visible or audible signal, marking each increment of needle tip exposed by operation of the adjustable needle stop.

US Patent:

7097832, Aug 29, 2006

Filed:

Mar 30, 2000

Appl. No.:

09/868411

Inventors:

Ran Kornowski - Ramat hasharon IL, US
Shmuel Fuchs - Rockville MD, US
Stephen E. Epstein - Rockville MD, US
Martin B. Leon - New York NY, US

Assignee:

Myocardial Therapeutics, Inc. - San Diego CA

International Classification:

A01N 63/00
C12N 5/00
C12N 5/06

US Classification:

424 937, 435384, 435372

Abstract:

A method of treating cardiac or myocardial conditions comprises the administration of an effective amount of autologous bone marrow. The bone marrow may optionally be stimulated and/or administered in combination with a pharmaceutical drug, protein, gene or other factor or therapy that may enhance bone marrow production of angiogenic growth factors and/or promote endothelial cell proliferation or migration or blood vessel formation.

US Patent:

7527932, May 5, 2009

Filed:

Nov 12, 2002

Appl. No.:

10/495081

Inventors:

Stephen E. Epstein - Rockville MD, US
Juanhui Zhu - Potomac MD, US

Assignee:

MedStar Research Institute, Inc. - Washington DC

International Classification:

G01N 33/53
G01N 33/564
C12Q 1/60

US Classification:

435 71, 435 721, 435 724, 435 78, 435 11, 436506, 436518, 436536, 436 86, 436 87, 436811

Abstract:

An individual's risk profile for developing a cardiovascular disorder or for experiencing a cardiovascular event is determined by 1) measuring levels of certain stress-evoked proteins including heat shock proteins (HSPs), cytokines, adhesion molecules, chemokines, and the like, or titers of the antibodies targeted to them, or 2) determining the number of seropositive responses to a group of pathogens that have been associated with the presence of atherosclerosis and/or clinical events related to atherosclerosis. The measured levels are compared with clinically derived standards that define the association of these markers with cardiovascular disease. These markers are independent of traditionally recognized risk factors.

US Patent:

8420590, Apr 16, 2013

Filed:

Nov 30, 2007

Appl. No.:

12/516961

Inventors:

Anton Wellstein - Washington DC, US
Marcel O. Schmidt - Washington DC, US
Stephan Zbinden - Wabern, CH
Mary Susan Burnett - Fairfax VA, US
Stephen E. Epstein - Rockville MD, US

Assignee:

Georgetown University - Washington DC
MedStar Health Research Institute, Inc. - Washington DC

International Classification:

A61K 38/16
A61P 35/00
C07K 14/00

US Classification:

514 11, 514 133, 514 137, 530324, 530370

Abstract:

Described herein are polypeptides that home to developing microvasculature, (also referred to as developing microvessels), such as newly developing microvasculature in mammals, particularly in humans, and to DNA that encodes such polypeptides. These polypeptides are referred to herein as developing microvasculature homing polypeptides. In a specific embodiment, the homing peptides are collateral vessel endothelia (CVE) homing polypeptides, which have been shown to home to collateral vessel endothelia after ischemia.

US Patent:

20030100499, May 29, 2003

Filed:

Aug 29, 2002

Appl. No.:

10/230390

Inventors:

Stephen Epstein - Rockville MD, US

International Classification:

A61K048/00
A61K038/17
C12Q001/00
C12M001/34

US Classification:

514/012000, 514/044000, 435/004000, 435/287100

Abstract:

The invention provides in vitro methods useful for screening compositions and methodologies in the treatment and prevention of coronary artery disease and, in particular, restenosis. The invention also provides devices and compositions that are used in the methods.

US Patent:

20030170673, Sep 11, 2003

Filed:

Oct 2, 2002

Appl. No.:

10/262659

Inventors:

Stephen Epstein - Rockville MD, US
Sarfraz Durrani - Arlington VA, US

International Classification:

C12Q001/68

US Classification:

435/006000

Abstract:

Methods are provided for estimating the risk of developing restenosis or of atherosclerosis in an individual. Methods and compositions for treating or preventing restenosis or atherosclerosis also are provided.